Screening for cervical cancer: Choices & dilemmas

Area of Science:

• Oncology
• Public Health
• Molecular Diagnostics

Background:

• Cervical cancer is a significant global health issue, ranking as the fourth most common cancer in women worldwide.
• The World Health Organization has set an ambitious target to eliminate cervical cancer by 2030, requiring 70% coverage of lifetime screening.
• Current screening modalities include cytology, human papillomavirus (HPV) DNA testing, and visual inspection, with precision tests enhancing specificity.

Purpose of the Study:

• To review current cervical cancer screening methods and their global implementation strategies.
• To identify challenges in achieving uniform screening coverage and managing HPV-positive populations.
• To discuss the integration of advanced biomarkers and screening guidelines for vaccinated individuals.

Main Methods:

• Review of existing literature on cervical cancer screening techniques.
• Analysis of global screening guidelines and implementation hurdles.
• Evaluation of precision screening tests, including molecular and protein biomarkers.

Main Results:

• Human papillomavirus (HPV) DNA testing, often combined with cytology, is the preferred global screening method.
• Visual inspection tests remain crucial in resource-limited settings.
• Enhanced specificity is achieved through precision tests like DNA methylation, p16 immunostaining, and HPV mRNA testing.

Conclusions:

• Uniform and systematic implementation of cervical cancer screening programs, including effective recall systems, is a major challenge.
• Ongoing controversies surround the management of HPV-positive women and the development of screening guidelines for vaccinated populations.
• Continued research and strategic planning are essential to achieve the goal of cervical cancer elimination.